Adagene Inc. (ADAG) Stock

About Adagene Inc.

Adagene Inc. functions as a clinical-stage biopharmaceutical organization, primarily concentrating on the identification, evolution, and fabrication of monoclonal antibody-based therapeutics engineered to combat various types of cancer. The company's developmental pipeline encompasses several investigational assets currently undergoing human trials. Among these is ADG106, a human ligand-blocking agonistic anti-CD137 monoclonal antibody, which is navigating Phase 1b/2 clinical assessment for individuals with advanced solid tumors and non-Hodgkin's lymphoma. Additionally, Adagene is progressing ADG126, a fully-human anti-CTLA-4 mAb, and ADG116, another human ligand-blocking anti-CTLA-4 mAb, both of which are advancing through Phase 1 studies for the treatment of advanced or metastatic solid tumors. Further along, ADG104, an anti-PD-L1 mAb, is in Phase 2 clinical development, and the innovative anti-CSF-1R mAb, ADG125, is undergoing Phase 1 trials. Beyond its clinical-stage programs, the firm also maintains an active preclinical portfolio. This includes ADG206, a masked, Fc engineered anti-CD137 agonistic POWERbody; ADG153, a masked anti-CD47 IgG1 SAFEbody, which is being explored for hematologic and solid tumor indications; ADG138, a novel HER2xCD3 POWERbody designed to target HER2-expressing solid tumors; and ADG152, a CD20xCD3 POWERbody under investigation for its potential to minimize off-tumor toxicities. Adagene Inc. was founded in 2011 and its principal operations are based in Suzhou, China.

Adagene Inc. is headquartered in CN.

Adagene Inc. (ADAG) stock trades at $3.67 with a market capitalization of $138.17M. The stock is valued at a negative price-to-earnings (P/E) ratio of -7.78, reflecting a net loss over the last twelve months, price-to-book of 3.94, price-to-sales of 17.96. Over the past 52 weeks the stock has ranged between $1.30 and $4.85, and currently trades 24.3% below its 52-week high.

On profitability, Adagene Inc. generates a return on equity (ROE) of -48.20% (negative, reflecting a net loss), return on capital employed of -40.48%, an operating margin of -279.39%, a net profit margin of -229.49%.

Official website: www.adagene.com

Adagene Inc. by the numbers, 2018–2025

Between 2018 and 2025 Adagene Inc. reported revenue of $2.0M rising to $8.0M, a change of +300.0% across 8 years. Compounded, revenue has grown —% a year over five years, -3.9% over three, —% over the last twelve months. Net profit fell to $-18.0M.

Operating margin went from -1147.1% in 2018 to -279.5% in 2025, a gain of 867.6 percentage points. The most recent net margin is -229.49%. On a trailing twelve-month basis to Dec '25, revenue is $8.0M and net profit $-52.0M.

Borrowings rose from $2.0M to $6.0M, cash on hand is $74.5M, cash from operations was $-16.0M in the latest year, positive in 0 of the last 8.

Return on equity has averaged -57.2% over five years, and was -51.4% in the most recent year.

The share price itself has compounded at -27.7% a year over five years, 36.0% over three, 93.2% over the last year. Past price movement is history, not a forecast.

Figures are as reported and in the company's own reporting currency. They describe what has already happened and carry no implication about what follows.

Adagene Inc. (ADAG) — frequently asked questions